Wave Life Sciences

Q2 FY2026 EarningsQ2 FY26 results missed consensus estimates on both top and bottom lines, with revenue of $2.3M significantly below the $7.1M expected. The GAAP EPS of -$0.34 missed the consensus mean of -$0.30 due to higher-than-anticipated operating expenses in R&D and G&A. Despite the financial miss, the company maintains a robust cash position of $490.6M with a runway extended into Q3 2028, and progress in the WVE-007 and WVE-006 clinical programs remains the primary driver of future value.